Laboratorios Farmaceuticos Rovi

Laboratorios Farmaceuticos Rovi (ROVI) investor relations material

Laboratorios Farmaceuticos Rovi Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.

Q2 2026 earnings summary23 Jul, 2026

Executive summary

Total revenue rose 13% year-over-year to €357.0M in H1 2026, with operating revenue up 9% to €344.2M, driven by a 38% surge in CDMO sales and strong Okedi® growth, while heparin franchise sales declined 4%.
Gross profit increased 21% to €237.1M, with gross margin expanding by 6.5pp to 68.9%, supported by R&D aid, CDMO growth, Okedi®, and lower LMWH raw material prices.
EBITDA jumped 85% to €121.2M (35.2% margin), but excluding a €62.4M non-recurring gain (badwill) from the Phoenix facility acquisition, EBITDA fell 10% to €58.8M.
Net profit more than doubled to €84.4M, up 113% year-over-year.
Acquisition of the Phoenix, Arizona injectable facility completed, generating a €62.4M gain on bargain purchase.

Financial highlights

Operating revenue: €344.2M (+9% YoY); Total revenue: €357.0M (+13% YoY); CDMO sales: €106.3M (+38% YoY).
Gross profit: €237.1M (+21% YoY); Gross margin: 68.9% (+6.5pp YoY).
EBITDA: €121.2M (+85% YoY, 35.2% margin); EBIT: €103.2M (+103% YoY, 30.0% margin); Net profit: €84.4M (+113% YoY, 24.5% margin).
Free cash flow: €64.7M (vs. €7.5M in H1 2025); Capex: €30.4M (+46% YoY).
Net cash position: €22.5M (vs. net debt of €21.9M at Dec 2025); Gross cash: €130.2M.

Outlook and guidance

Operating revenue for 2026 expected to grow low- to mid-single digits vs. 2025.
Heparin franchise sales forecast to decline mid-single digits due to high partner inventories and pricing pressure.
SG&A (excluding Phoenix) projected to rise mid- to high-single digits in 2026.
Okedi® sales guidance maintained, with strong uptake expected to continue; two phase III clinical trials ongoing.
Prudent outlook maintained amid competitive and regulatory uncertainties.

EBITDA margin impact excluding Phoenix badwill

Drivers for revised 2026 LMWH sales guidance

Letrozole SIE and Risperidone QUAR Phase III dates

Partial view of Summaries dataset, powered by Quartr API

AI can get things wrong. Verify important information.

Research faster. Power your platform.

Latest events from Laboratorios Farmaceuticos Rovi

View more events

Next Laboratorios Farmaceuticos Rovi earnings date

Q3 20265 Nov, 2026

Companies

Laboratorios Farmaceuticos Rovi

Your earnings  season toolkit.

Download

Free on both iOS & Android.

Next Laboratorios Farmaceuticos Rovi earnings date

Q3 20265 Nov, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

Leroy DaleyApp Store

One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.

Eferix Drawings Google Play

This is genuinely one of the cleanest and fastest finance apps out there to track the market.

anuj283App Store

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I can't remember the last time an app had such a positive impact on my investment process.

@ankurshah47_ x.com

Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.

Amina0781App Store

Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.

@theshortbearx.com

I’m actually shocked at just how much I like Quartr. If you’re an analyst & need a strong web tool + mobile app that syncs properly, saves you from manually dialing into calls.

@endthepods x.com

A must have for every investor. includes all quarterly reports with earnings calls and transcripts in single app

Abdulla AlnaamaGoogle Play